Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.

Berger AK, Zschaebitz S, Komander C, Jäger D, Haag GM.

World J Gastroenterol. 2015 Apr 28;21(16):4911-8. doi: 10.3748/wjg.v21.i16.4911.

2.

Primary esophageal adenocarcinoma with distant metastasis to the skeletal muscle.

Sohda M, Ojima H, Sano A, Fukai Y, Kuwano H.

Int Surg. 2014 Sep-Oct;99(5):650-5. doi: 10.9738/INTSURG-D-13-00166.1.

3.

Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study.

Cooper S, Menon S, Nightingale P, Trudgill Nj.

United European Gastroenterol J. 2014 Apr;2(2):91-8. doi: 10.1177/2050640614523596.

4.

Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV.

Dis Esophagus. 2014 Nov-Dec;27(8):757-63. doi: 10.1111/dote.12147. Epub 2013 Oct 7.

5.

AXL mediates TRAIL resistance in esophageal adenocarcinoma.

Hong J, Belkhiri A.

Neoplasia. 2013 Mar;15(3):296-304.

6.

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.

Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE.

Br J Cancer. 2013 Feb 19;108(3):519-26. doi: 10.1038/bjc.2012.588. Epub 2013 Jan 15.

7.

Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy.

Kramer JR, Arney J, Chen J, Richardson P, Duan Z, Street RL Jr, Hinojosa-Lindsey M, Naik AD, El-Serag HB.

BMC Health Serv Res. 2012 Aug 28;12:288. doi: 10.1186/1472-6963-12-288.

8.

Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy.

Navarini D, Gurski RR, Madalosso CA, Aita L, Meurer L, Fornari F.

Gastroenterol Res Pract. 2012;2012:941954. doi: 10.1155/2012/941954. Epub 2012 Jun 26.

9.

Probe-Based Confocal Laser Endomicroscopy to Guide Real-Time Endoscopic Therapy in Barrett's Esophagus with Dysplasia.

Johnson EA, De Lee R, Agni R, Pfau P, Reichelderfer M, Gopal DV.

Case Rep Gastroenterol. 2012 May;6(2):285-92. doi: 10.1159/000338835. Epub 2012 May 23.

10.

Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.

Hong J, Katsha A, Lu P, Shyr Y, Belkhiri A, El-Rifai W.

Cancer Res. 2012 Sep 1;72(17):4504-14. doi: 10.1158/0008-5472.CAN-12-1119. Epub 2012 Jun 28.

11.

Association of insulin and insulin-like growth factors with Barrett's oesophagus.

Greer KB, Thompson CL, Brenner L, Bednarchik B, Dawson D, Willis J, Grady WM, Falk GW, Cooper GS, Li L, Chak A.

Gut. 2012 May;61(5):665-72. doi: 10.1136/gutjnl-2011-300641. Epub 2011 Sep 19.

12.

Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?

Keld RR, Ang YS.

World J Gastroenterol. 2011 Jun 21;17(23):2781-90. doi: 10.3748/wjg.v17.i23.2781.

13.

Iron intake and markers of iron status and risk of Barrett's esophagus and esophageal adenocarcinoma.

O'Doherty MG, Abnet CC, Murray LJ, Woodside JV, Anderson LA, Brockman JD, Cantwell MM.

Cancer Causes Control. 2010 Dec;21(12):2269-79. doi: 10.1007/s10552-010-9652-0. Epub 2010 Oct 10.

14.

Gastroesophageal reflux disease: medical or surgical treatment?

Liakakos T, Karamanolis G, Patapis P, Misiakos EP.

Gastroenterol Res Pract. 2009;2009:371580. doi: 10.1155/2009/371580. Epub 2009 Dec 31.

15.

Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol.

Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani JA, Huang P.

Antioxid Redox Signal. 2009 May;11(5):1083-95. doi: 10.1089/ARS.2008.2321.

16.

The association between obesity and GERD: a review of the epidemiological evidence.

El-Serag H.

Dig Dis Sci. 2008 Sep;53(9):2307-12. doi: 10.1007/s10620-008-0413-9. Epub 2008 Jul 24. Review.

17.

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades.

Gockel I, Sultanov FS, Domeyer M, Goenner U, Junginger T.

BMC Cancer. 2007 Jun 29;7:114.

18.

Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003.

van Blankenstein M, Looman CW, Siersema PD, Kuipers EJ, Coebergh JW.

Br J Cancer. 2007 Jun 4;96(11):1767-71. Epub 2007 May 15.

19.

Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas.

Lee OJ, Hong SM, Razvi MH, Peng D, Powell SM, Smoklin M, Moskaluk CA, El-Rifai W.

Neoplasia. 2006 Oct;8(10):843-50.

20.

Endoscopic screening and surveillance for Barrett's esophagus--clinical implications.

Barr H, Kendall C, Bazant-Hegemark F, Moayyedi P, Shetty G, Stone N.

MedGenMed. 2006 Jun 27;8(2):88. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk